Prognostic factors on posttransplantation outcome in multivariate analysis
| Clinical variables . | OS . | Probability of relapse . | TRM . | |||
|---|---|---|---|---|---|---|
| HR . | P . | HR . | P . | HR . | P . | |
| Recipient sex | 1.16 | .7 | 1.10 | .68 | 0.45 | .12 |
| Recipient age* | 1.03 | .001 | 1.007 | .72 | 1.029 | .018 |
| Time from diagnosis to allo-SCT* | 0.99 | .36 | 0.98 | .21 | 0.91 | .66 |
| Year of transplantation, 1990-1995 versus 1996-2000 versus 2001-2006 | 0.62 | .06 | 0.81 | .14 | 0.50 | .009 |
| WHO categories* | 1.21 | .017 | 1.23 | .01 | 1.01 | .82 |
| Cytogenetic risk* | 1.21 | .09 | 1.87 | .04 | 1.07 | .74 |
| Transfusion dependency* | 1.59 | .01 | 1.28 | .54 | 1.56 | .037 |
| ANC* | 0.99 | .93 | 1.01 | .77 | 0.98 | .36 |
| Hb level* | 1.01 | .09 | 0.94 | .61 | 1.01 | .24 |
| PLT level* | 0.99 | .23 | 0.99 | .17 | 0.92 | .37 |
| Disease stage at transplantation, active/progressive disease vs complete remission | 0.64 | .036 | 0.34 | .017 | 0.81 | .44 |
| Source of HSCs, peripheral blood vs bone marrow | 1.07 | .72 | 1.2 | .55 | 1.52 | .09 |
| Type of donor, HLA-identical sibling vs MUD | 1.67 | .006 | 0.32 | .01 | 1.97 | .001 |
| Conditioning regimen, standard conditioning vs RIC | 0.70 | .10 | 2.5 | .005 | 0.53 | .032 |
| Clinical variables . | OS . | Probability of relapse . | TRM . | |||
|---|---|---|---|---|---|---|
| HR . | P . | HR . | P . | HR . | P . | |
| Recipient sex | 1.16 | .7 | 1.10 | .68 | 0.45 | .12 |
| Recipient age* | 1.03 | .001 | 1.007 | .72 | 1.029 | .018 |
| Time from diagnosis to allo-SCT* | 0.99 | .36 | 0.98 | .21 | 0.91 | .66 |
| Year of transplantation, 1990-1995 versus 1996-2000 versus 2001-2006 | 0.62 | .06 | 0.81 | .14 | 0.50 | .009 |
| WHO categories* | 1.21 | .017 | 1.23 | .01 | 1.01 | .82 |
| Cytogenetic risk* | 1.21 | .09 | 1.87 | .04 | 1.07 | .74 |
| Transfusion dependency* | 1.59 | .01 | 1.28 | .54 | 1.56 | .037 |
| ANC* | 0.99 | .93 | 1.01 | .77 | 0.98 | .36 |
| Hb level* | 1.01 | .09 | 0.94 | .61 | 1.01 | .24 |
| PLT level* | 0.99 | .23 | 0.99 | .17 | 0.92 | .37 |
| Disease stage at transplantation, active/progressive disease vs complete remission | 0.64 | .036 | 0.34 | .017 | 0.81 | .44 |
| Source of HSCs, peripheral blood vs bone marrow | 1.07 | .72 | 1.2 | .55 | 1.52 | .09 |
| Type of donor, HLA-identical sibling vs MUD | 1.67 | .006 | 0.32 | .01 | 1.97 | .001 |
| Conditioning regimen, standard conditioning vs RIC | 0.70 | .10 | 2.5 | .005 | 0.53 | .032 |
PLT indicates platelet; and HSCs, hematopoietic stem cells.
Clinical and demographic variables were evaluated at the time of transplantation in patients undergoing allo-SCT upfront, and before remission-induction chemotherapy in patients receiving treatment before transplantation.